Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Bladder Cancer - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
1855 pages
Colon Cancer - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
1184 pages
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
627 pages
Huntington Disease - Pipeline Review, H1 2020
US$ 2,000.00
... . The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
390 pages
Medulloblastoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
380 pages
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
71 pages
Myelodysplastic Syndrome - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
1667 pages
Non-Small Cell Lung Cancer - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
4664 pages
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020
US$ 2,500.00
... Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
3103 pages
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
2766 pages
Hypertension - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
772 pages
Macular Edema - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
92 pages
Multiple Sclerosis - Pipeline Review, H1 2020
US$ 2,500.00
... . The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
1114 pages
Colorectal Cancer - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
3889 pages
Female Sexual Dysfunction - Pipeline Review, H1 2020
US$ 2,000.00
... . The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
84 pages
Retinal Vein Occlusion - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
93 pages
Age Related Macular Degeneration - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
864 pages
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
1561 pages
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
2815 pages
Ovarian Cancer - Pipeline Review, H1 2020
US$ 2,500.00
... releases. The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
3802 pages
Wounds - Pipeline Review, H1 2020
US$ 2,000.00
... pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development ...
June 2020
255 pages
Neuroendocrine Tumors - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
795 pages
Keloids - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
64 pages
Peptic Ulcers - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
65 pages
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
42 pages
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
260 pages
Recurrent Malignant Glioma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
55 pages
Progressive Supranuclear Palsy - Pipeline Review, H1 2020
US$ 2,000.00
... . The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
113 pages
Western Equine Encephalitis - Pipeline Review, H1 2020
US$ 2,000.00
... . The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
33 pages
Radiodermatitis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
57 pages
Canavan Disease - Pipeline Review, H1 2020
US$ 2,000.00
... . The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
35 pages
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
282 pages
Encephalopathy - Pipeline Review, H1 2020
US$ 2,000.00
... . The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
81 pages
Familial Amyloid Neuropathies - Pipeline Review, H1 2020
US$ 2,000.00
... . The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
98 pages
Graves' Ophthalmopathy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
82 pages
Hyperglycemia - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
35 pages
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
103 pages
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
68 pages
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
110 pages
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under ...
June 2020
98 pages
Myocardial Fibrosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
June 2020
87 pages
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
327 pages
Poliomyelitis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
91 pages
Sicca Syndrome (Sjogren) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
189 pages
Toxoplasmosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
48 pages
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2020
US$ 2,000.00
... Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under ...
June 2020
60 pages
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
June 2020
152 pages
Dengue Fever - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
June 2020
179 pages
